Mini Mental State Examination and Logical Memory scores for entry into Alzheimer’s disease trials by Kimberly R. Chapman et al.
RESEARCH Open Access
Mini Mental State Examination and Logical
Memory scores for entry into Alzheimer’s
disease trials
Kimberly R. Chapman1, Hanaan Bing-Canar1, Michael L. Alosco1,2, Eric G. Steinberg1, Brett Martin1,3,
Christine Chaisson1,3,4, Neil Kowall1,2,5,6, Yorghos Tripodis1,4 and Robert A. Stern1,2,7,8*
Abstract
Background: Specific cutoff scores on the Mini Mental State Examination (MMSE) and the Logical Memory (LM)
test are used to determine inclusion in Alzheimer’s disease (AD) clinical trials and diagnostic studies. These
screening measures have known psychometric limitations, but no study has examined the diagnostic accuracy of
the cutoff scores used to determine entry into AD clinical trials and diagnostic studies.
Methods: ClinicalTrials.gov entries were reviewed for phases II and III active and recruiting AD studies using the
MMSE and LM for inclusion. The diagnostic accuracy of MMSE and LM-II cutoffs used in AD trials and diagnostic
studies was examined using 23,438 subjects with normal cognition, mild cognitive impairment (MCI), and AD
dementia derived from the National Alzheimer’s Coordinating Center database.
Results: MMSE and LM cutoffs used in current AD clinical trials and diagnostic studies had limited diagnostic
accuracy, particularly for distinguishing between normal cognition and MCI, and MCI from AD dementia. The
MMSE poorly discriminated dementia stage.
Conclusions: The MMSE and LM may result in inappropriate subject enrollment in large-scale, multicenter studies
designed to develop therapeutics and diagnostic methods for AD.
Keywords: Alzheimer’s disease, Clinical trials, MMSE, Logical Memory, Eligibility, Mild cognitive impairment,
Neurodegenerative disease
Background
Alzheimer’s disease (AD) clinical trials and diagnostic
studies are responsible for the testing and development
of therapeutics and diagnostic methods for AD. These
large-scale, multicenter studies must have strict inclu-
sion criteria to accurately identify and discriminate nor-
mal cognition, mild cognitive impairment (MCI), and
AD dementia and recruit the population of interest to
facilitate internal and external validity. This, however, is
no straightforward task. Although there have been great
gains in the development of biomarkers for the accurate
in vivo diagnosis and early detection of AD (e.g., lumbar
puncture, positron emission tomography) [1–3], these
are invasive procedures typically conducted following
initial screening methods. Instead, investigators in AD
clinical trials and diagnostic studies often initially rely on
brief cognitive screening tests to detect cognitive impair-
ment and classify patients, using a variety of research-
derived cut scores, as having normal cognition, MCI, or
dementia. The Mini Mental State Examination (MMSE)
[4] and the Wechsler Memory Scale (WMS) Logical
Memory (LM) test [5] are two screening measures com-
monly used to determine inclusion in these studies.
The use of the MMSE and LM in AD clinical trials
and diagnostic studies to ascertain diagnostic status and
determine inclusion may be methodologically problem-
atic. Numerous studies have demonstrated the psycho-
metric limitations of the MMSE, such as large ceiling
and floor effects, and sensitivity to practice effects [6–8].
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The utility of the MMSE in detecting MCI and AD de-
mentia is indeed limited [9–11]. Perneczky et al. [12] ex-
amined the correspondence between the MMSE and
Clinical Dementia Rating (CDR) scores and found the
MMSE lacked accuracy in the identification of patients
with MCI or mild AD dementia.
Scores on the delayed recall dimension of LM (LM-II)
can also lack diagnostic utility when administered in iso-
lation. LM-II is associated with significant learning
biases [13], and practice effects may undermine its de-
tection of impairment, particularly among potential AD
trial subjects who have had repeated exposure to LM.
For example, LM has been administered annually to all
participants in the National Institutes of Health (NIH)-
funded Alzheimer’s Disease Centers (ADCs), as part of the
National Alzheimer’s Coordinating Center (NACC) Uni-
form Data Set (UDS), for approximately 20 years [14]. The
consortium of these centers is an important source of en-
rollment for AD clinical trials. The ability of the LM rela-
tive to other tests to accurately detect AD has also been
questioned [15], and healthy older adults frequently dem-
onstrate impairments on LM retention [16]. Performance
on LM may also be relatively more sensitive to executive
dysfunction than episodic memory [17].
Given the diagnostic and psychometric limitations of
the MMSE and LM, many AD clinical trials and diag-
nostic studies in which these instruments are used to de-
termine eligibility may be inappropriately including or
excluding subjects. This could influence the reliability
and validity of study outcomes due to sampling biases.
The recent phase III bapineuzumab and solanezumab
trials both included the MMSE as part of study entry
criteria, and both failed to meet primary efficacy end-
points [18, 19]. (In fact, no new compounds for the
treatment of AD have been approved by the U.S. Food
and Drug Administration since 2003.) Although research
from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) has been at the forefront of the development of
diagnostic methods and biomarkers for AD, ADNI also
relies on MMSE and LM scores to determine eligibility.
The extent to which MMSE and LM scores are being
used as eligibility criteria in AD clinical trials and diag-
nostic studies is unclear, and no study has examined
whether the cutoffs used in these studies accurately cor-
respond to AD spectrum clinical diagnoses. The purpose
of the present study was twofold: (1) to identify all active
and recruiting phases II and III AD clinical trials and
diagnostic studies in the United States to determine the
extent to which the MMSE and LM are used as eligibil-
ity criteria and to identify the cutoff scores used to as-
certain AD diagnostic category; and (2) to exploit the
large NACC database to determine the correspondence
between MMSE and LM cutoff scores used in current
clinical trials and diagnostic studies and AD spectrum
diagnoses made by multidisciplinary diagnostic confer-
ence teams. The MMSE is often used to determine de-
mentia severity in clinical and research settings, and past
work [12] suggests this may be problematic due to the
weak correspondence between the MMSE and the CDR
(the gold standard for rating dementia severity), particu-
larly at the mild end of the disease spectrum. Therefore,
in the present study we sought, as a secondary aim, to
replicate and expand upon the previous smaller-scale
study on the MMSE and CDR [12] by examining their
correspondence in the large NACC dataset.
Methods
Search criteria
We first examined the extent to which the MMSE and
LM are used in AD clinical trials and diagnostic studies,
as well as the cutoff scores employed in these studies.
To do so, all phases II and III recruiting and active AD
trials were identified in the ClinicalTrials.gov database.
The search was limited to U.S. trials that listed “Alzhei-
mer’s disease” as a keyword. Inclusion criteria as they
pertained to MMSE and LM and their cutoffs were ob-
tained from the inclusion description under “Eligibility.”
Subjects
The diagnostic accuracy of MMSE and LM cutoffs used in
AD trial and diagnostic studies was tested using subjects in
the NACC database diagnosed with normal cognition
(n = 10,741), MCI (n = 5883), and AD dementia (n = 6814).
The NACC, established by the National Institute on Aging
in 1999 to promote collaborative AD research, is a publicly
accessible, longitudinal database of standardized clinical
data gathered from 34 past and present ADCs across the
United States. The regional ADCs are based in university
medical centers, and recruitment is carried out via neur-
ology referrals and community outreach. Each year begin-
ning in 2005, the ADCs have contributed standardized
cognitive, behavioral, and functional data for each partici-
pant to a UDS that now forms the NACC-UDS database.
For full descriptions of the NACC-UDS, please refer to
publications by Weintraub et al. [14], Beekly et al. [20, 21],
and Morris et al. [22]. Before engagement in the research
registry, written informed consent was obtained by all study
participants or their legally authorized representatives. All
aspects of the study adhered to necessary ethical guidelines
and were approved by the local ADC’s human subjects re-
view board.
A formal data request to NACC for this study was ap-
proved (proposal ID 606), and data were provided on 28
September 2015. The sample was restricted to initial
visits of subjects between the ages of 50 and 100 years
with a diagnosis of normal cognition, MCI, or primary
possible or probable AD dementia. Baseline evaluations
for the current sample occurred between 2005 and 2015.
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Data queried included the UDS cognitive test battery
(see below for version), diagnostic status, CDR score,
and demographic variables. The sample was further re-
stricted to those who completed the English version of
the MMSE. See Table 1 for study variables.
Diagnostic categories
For the current NACC sample, 23.0 % of neurological
diagnoses were made by a single clinician and 77.0 % of
the diagnoses were assigned through multidisciplinary
diagnostic consensus conferences composed of neurolo-
gists, neuropsychologists, geriatricians, and geriatric psy-
chiatrists. Consensus diagnoses were made following
presentation and discussion of all examinations, UDS
(and other) test findings (including neuroimaging and
other biomarkers, if available), and psychosocial and
medical history. At the time of data collection for this
study, AD dementia was diagnosed on the basis of the
National Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer’s Disease and Related
Disorders Association criteria [23]. MCI diagnosis was
based on criteria defined by Winblad et al. [24].
Measures
Mini Mental State Examination
The MMSE is a 30-item assessment of global cognitive
status that taps into domains such as orientation, con-
centration, attention, verbal learning (without delayed
recall), naming, and visuoconstruction [4]. Despite its
weaknesses, the MMSE has long been used to detect
and monitor dementia progression.
Logical Memory test
The LM subtest of the WMS-R is a standardized assess-
ment of narrative episodic memory [5]. A short story is
orally presented, and the examinee is asked to recall the
story verbatim (immediate recall). Approximately 20 or
30 min later, free recall of the story is again elicited
(delayed recall). Of the NACC sample, 11,569 subjects
were administered the UDS cognitive battery version 1
and 11,869 were given version 2. Between 2005 and
2007, two version 1 examinations were administered (1.1
and 1.2), with version 1.1 having a delayed story recall of
30 min and version 1.2 being 20 min. The UDS version
2 retained the 20-min recall. For all UDS versions, LM
Story A delayed recall was used and the only difference
from version 1.1 to versions 1.2 and 2 was the delay
interval. Of note, we were unable to distinguish between
subjects who received versions 1.1 and 1.2, but the dif-
ferences in the delay intervals have been shown not to
be associated with number of units recalled [14].
Clinical Dementia Rating
The CDR is a widely used, valid, and reliable tool for sta-
ging dementia severity [25–27]. Specifically, the CDR is
standardized for multicenter use, has demonstrated good
interrater reliability and criterion validity, and has been
shown to predict neuropathology [26]. In fact, even
without an informant, recent work in community-
dwelling elderly shows the CDR exhibits strong internal
consistency (Cronbach’s α 0.83–0.84) and good interra-
ter reliability (0.95 for global rating) and test-retest reli-
ability (κ = 0.80 for global rating) [28]. The CDR assesses
the extent of a person’s impairment in six domains: mem-
ory, orientation, judgment/problem-solving, community
affairs, home and hobbies, and personal care. An algo-
rithm is used to create an overall rating of impairment
severity: 0 (no dementia), 0.5 (questionable dementia), 1.0
(mild dementia), 2.0 (moderate dementia), or 3.0 (severe
dementia). Typically, a score of 0.5 is given to individuals
with a diagnosis of MCI [25].
Statistical analyses
Subjects were excluded for missing data on the MMSE
or LM that was due to physical, cognitive, or behavioral
(including refusal) problems that interfered with testing.
Table 1 NACC sample characteristics
Normal cognition MCI AD dementia P value
Number of subjects 10,741 5883 6814 –
Age, yr, mean (SD) 71.92 (9.40) 73.87 (8.93) 75.28 (9.28) <0.001
Education,a yr, mean (SD) 15.74 (2.86) 15.21 (3.21) 14.53 (3.30) <0.001
Female sex, n (%) 7047 (65.6) 2907 (49.4) 3689 (54.1) <0.001
White race,a n (%) 8713 (81.3) 4682 (79.8) 5639 (82.8) <0.01
Global CDR, mean (SD) 0.05 (0.15) 0.46 (0.17) 1.02 (0.57) <0.001
MMSE, mean (SD) 28.88 (1.41) 27.11 (2.43) 20.92 (5.50) <0.001
Logical Memory-II raw score, mean (SD) 12.17 (4.13) 6.92 (4.64) 1.82 (2.88) <0.001
Abbreviations: NACC National Alzheimer’s Coordinating Center, CDR Clinical Dementia Rating, MMSE Mini Mental State Examination, MCI mild cognitive impairment,
AD Alzheimer’s disease, SD standard deviation
Post hoc analyses showed significant differences across all three groups
aDue to missing data, sample size for education is reduced to 10,695 for normal cognition, 5863 MCI, and 6779 for AD dementia and sample size for race is 10,721
normal cognition, 5869 MCI, and 6807 AD
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Receiver operating characteristic (ROC) curves were ex-
amined to evaluate the accuracy [area under the ROC
curve (AUC)] of the MMSE and LM cutoffs used in AD
clinical trials and diagnostic studies (results presented
below) in distinguishing the diagnostic groups. The
MMSE and LM-II were transformed to binary variables
(i.e., above and below the identified cutoff ) and served
as the test variable. An AUC value of 0.75 was consid-
ered to be clinically meaningful [29]. ROC curve ana-
lyses were repeated with MMSE and LM as continuous
test variables to obtain the sensitivity and specificity
values of the cutoffs used in AD clinical trials and diag-
nostic studies. Positive and negative predictive values
(PPVs and NPVs, respectively) were then calculated to
determine the diagnostic accuracy of the cutoffs in the
NACC sample. The prevalence of MCI and AD demen-
tia used for the calculation of PPV and NPV was based
on the prevalence of MCI and AD dementia in this sam-
ple and, in some instances, varied according to the age
or educational group to which analyses were restricted.
κ Statistics were used to examine the level of agree-
ment between the MMSE and CDR groups. MMSE cut-
offs of 30, 29–26, 25–21, 20–11, and 10–0 have
previously been shown to map onto CDR scores (0, 0.5,
1.0, 2.0, and 3.0, respectively) and thus were used in this
study to define no, questionable, mild, moderate, and se-
vere dementia, respectively [12]. Standard convention
was used in the interpretation of κ values in terms of
level of agreement [30].
Results
Prevalence of MMSE and LM as inclusion criteria in AD
clinical trials and diagnostic studies
There were 111 phases II and III AD trials and diagnos-
tic studies that were listed as recruiting or active. Of
those 111, 64 (57.7 %) used the MMSE for eligibility cri-
teria, including randomized controlled treatment trials
“Effect of Passive Immunization on the Progression of
Mild Alzheimer’s Disease: Solanezumab (LY2062430)
Versus Placebo” (sponsored by Eli Lilly and Company)
and “Anti-Amyloid Treatment in Asymptomatic Alzhei-
mer’s Disease (A4 Study)” (sponsored by Eli Lilly and
Company, Alzheimer’s Disease Cooperative Study collab-
orator). The major multisite diagnostic study, Alzheimer’s
Disease Neuroimaging Initiative 2 (ADNI 2) (funded by
the National Institute on Aging, the National Institute of
Biomedical Imaging and Bioengineering, and private sec-
tor contributions facilitated by the Foundation of the
National Institutes of Health), was also found to use the
MMSE. MMSE cutoffs ranging from 3–14 to >27, but ≤24
and/or ≤26 most commonly defined the clinical spectrum
of AD. A majority of studies that use 26 primarily target
subjects with MCI or mild AD dementia.
Seven recruiting and active AD clinical trials use LM
to determine eligibility, and five of the seven use both
the MMSE and LM. All trials use the delayed recall
score of LM (i.e., LM-II). Notable trials include the
“Anti-Amyloid Treatment in Asymptomatic Alzheimer’s
Disease (A4 Study)” and “A Placebo-controlled, Double-
blind, Parallel-group, Bayesian Adaptive Randomization
Design and Dose-Regimen-find Study to Evaluate Safety,
Tolerability and Efficacy of BAN2401 in Subjects with
Early Alzheimer’s Disease” (sponsored by Eisai Inc.).
There was inconsistency with the WMS version used:
the BAN2401 uses WMS-IV, but other trials use the
WMS-R or the WMS-III. ADNI 2 also uses LM-II
(WMS-R) to determine study eligibility. ADNI 2 and the
A4 and BAN2401 trials use both the LM-II and MMSE.
Regarding LM-II cutoffs, the A4 trial uses 6–18 to define
asymptomatic AD. The BAN2401 trial cutoffs are age-
adjusted and include 50–64 years: ≤15; 65–69 years: ≤12;
70–74 years: ≤11; 75–79 years: ≤9; and 80–90 years ≤7.
ADNI 2 implements the following LM-II education-based
cutoffs:
 16 years of education: normal ≥9; early MCI = 9–11;
AD ≤8
 8–15 years of education: normal ≥5; early MCI = 5–9;
AD ≤4
 0–7 years of education: normal ≥3; early MCI = 3–6;
AD ≤2
AUC, PPV, and NPV for MMSE cutoff scores
AUC
On the basis of the above-described search results, we
tested the accuracy of MMSE scores ≤24 and/or ≤26 in dis-
tinguishing normal cognition from AD dementia and MCI,
respectively, and then MCI from AD dementia. Table 2
presents AUC values. The accuracy of an MMSE ≤26 was
suboptimal for MCI, but an MMSE of ≤24 was adequate
for detecting AD dementia.
PPV and NPV: normal cognition versus MCI
Table 3 provides PPVs and NPVs for MMSE cutoff
scores used in AD clinical trials and diagnostic studies.
Of note, we provide a range of MMSE cutoff scores
other than ≤24 and/or ≤26 to determine the accuracy
of other scores and to potentially facilitate decision-
making regarding optimal cutoff score use. The MMSE
score of 26 yielded a PPV and NPV of 64.6 % and
68.2 %, respectively, suggesting this cutoff is associated
with a >35 % chance that NACC subjects may be in-
accurately classified as having MCI or AD dementia.
MMSE scores <26 increased in PPV and declined in
NPV.
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PPV and NPV: normal cognition versus AD dementia
In the comparison between normal cognition and AD
dementia, there was a PPV of 97.0 % for the MMSE cut-
off of ≤24, but the NPV was only 80.8 %. The NPV sug-
gests there is a 19.2 % chance that NACC subjects with
AD dementia are not detected by this cutoff.
PPV and NPV: MCI versus AD dementia
Relative to normal cognition versus AD dementia, the
PPV and NPV for the MMSE cutoff of 24 were lower for
distinguishing between MCI and AD dementia (90.1 %
and 63.8 %, respectively).
MMSE and CDR score agreement
The level of agreement between the MMSE and CDR
scores improved across the AD spectrum (p < 0.001 for
all). Using MMSE cutoffs previously validated to dis-
criminate across CDR scores [12], κ values were the
worst for questionable dementia or MCI (κ = 0.15, slight
agreement). There was fair agreement for normal cogni-
tion (κ = 0.37), as well as mild (κ = 0.27) and moderate
Table 2 AUC values for MMSE and LM-II cutoffs used in AD clinical trials and diagnostic studies in NACC subjects
Normal cognition vs. MCI Normal cognition vs. AD dementia MCI vs. AD dementia
MMSE scores
MCI cutoff score ≤26 0.63 – –
AD dementia cutoff score ≤24 – 0.85 0.80
LM-II score (A4 Trial)
Cutoff score <6 0.67 0.92 0.74
LM-II score (BAN2401)
50–64 years old
Cutoff score ≤15 0.61 0.64 0.53
65–69 years old
Cutoff score ≤12 0.68 0.76 0.58
70–74 years old
Cutoff score ≤11 0.71 0.78 0.57
75–79 years old
Cutoff score ≤9 0.72 0.84 0.62
80–90 years old
Cutoff score ≤7 0.72 0.88 0.67
LM-II score (for early MCI in ADNI 2)
16+ years of education
Cutoff score ≤11 0.72 – –
8–15 years of education –
Cutoff score ≤9 0.70 – –
0–7 years of education –
Cutoff score ≤6 0.69 – –
LM-II score (for AD dementia in ADNI 2)
16+ years of education
Cutoff score ≤8 – 0.90 0.67
8–15 years of education
Cutoff score ≤4 – 0.92 0.76
0–7 years of education
Cutoff score ≤2 – 0.87 0.76
Abbreviations: NACC National Alzheimer’s Coordinating Center, MMSE Mini Mental State Examination, LM-II Wechsler Memory Scale Logical Memory-II, MCI mild
cognitive impairment, ADNI 2 Alzheimer’s Disease Neuroimaging Initiative 2, AUC area under the receiver operating characteristic curve
Cutoffs were chosen on the basis of those used in AD clinical trials and diagnostic studies: “Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease” (6–18 =
asymptomatic AD); “A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose-Regimen-find Study to Evaluate Safety,
Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease” (50–64 years: ≤15; 65–69 years: ≤12; 70–74 years: ≤11; 75–79 years: ≤9; 80–90
years ≤7; and ADNI 2 (16 years of education: normal ≥9; early MCI 9–11; AD ≤8; 8–15 years of education: normal ≥5; early MCI 5–9; AD ≤4; 0–7 years of education:
normal ≥3; early MCI 3–6; AD ≤2)
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(κ = 0.33) dementia. There was moderate agreement for
severe dementia (κ = 0.48).
AUC, PPV, and NPV for LM-II cutoff scores
AUC
The accuracy of all LM-II cutoff scores was clinically in-
adequate for distinguishing between normal cognition
and MCI (AUC <0.75 for nearly all) and was worst for
the BAN2401 trial cutoff of ≤15 in 50–64-year-olds
(AUC 0.61). A similar pattern emerged between MCI
and AD dementia. In terms of normal cognition versus
AD dementia, the LM-II cutoff of ≤15 in the BAN2401
trial for 50–64-year-olds was only 0.64; the AUC for all
remaining LM-II cutoffs was >0.75.
PPV and NPV: normal cognition versus MCI
Tables 4, 5, and 6 present PPVs and NPVs for LM-II cut-
off scores for the A4 and BAN2401 trials and ADNI 2.
The suggested LM-II cutoffs had a high probability of
inaccurate NACC diagnosis. The age-adjusted LM-II
cutoff of ≤15 used in the BAN2401 trial resulted in a
33.1 % probability that NACC subjects with MCI, aged
50–64 years, actually had MCI. NPV was lowest (72.8 %)
for the LM-II cutoff used for 80–90-year-olds. There
was a similar pattern for the remaining age categories.
Regarding ADNI 2 cutoffs that defined MCI, the PPV
reached as low as 52.2 % for NACC subjects with 16+
years of education. The NPV was <50.0 % for all LM-II
cutoffs among NACC subjects with 0–7 years of
education.
PPV and NPV: normal cognition versus AD dementia
The PPV for an LM-II score of 15 in 50–64-year-old
NACC subjects was 37.2 %, and it remained similar for
the other age categories. In terms of ADNI 2 cutoffs for
individuals with 16+ years of education, there was a
17.2 % chance that NACC subjects who did not have
AD dementia scored at or below the ADNI 2 defined
score for AD dementia. NPV was >90.0 % for almost all
AD dementia LM-II cutoffs, although the cutoff for
NACC subjects with 0–7 years of education had an NPV
of 58.4 %.
PPV and NPV: MCI versus AD Dementia
PPV was 53.9 % for the LM-II cutoff score of 15 in the
50–64-year-old group and 48.2 % for the cutoff of 12 in
the 65–69-year-old group. Almost all other PPVs were
below 70.0 %. NPV reached as low as 64.0 % for the
LM-II score of 2 in the 0–7 years of education group.
Discussion
Nearly 60 % of currently active and recruiting phases II
and III AD clinical trials and diagnostic studies rely on
MMSE scores to determine inclusion, and several use
LM-II test scores. MMSE and LM-II cutoffs used to deter-
mine eligibility were associated with a high probability of
inaccurate diagnostic classification in the >23,000 NACC
subjects with normal cognition, MCI, and AD dementia.
In the NACC sample, the MMSE and LM-II cutoff scores
lacked diagnostic accuracy for the identification of MCI,
and LM-II cutoffs poorly distinguished AD dementia from
MCI (AUC <0.75). It was the consistently low PPVs and
Table 3 PPV and NPV for AD clinical trial and diagnostic study
MMSE cutoff scores for normal cognition versus MCI and AD
dementia in NACC
MMSE score Sensitivity Specificity PPV NPV
Normal cognition (n = 10,741)
versus MCI (n = 5883)
18 0.4 100.0 85.2 64.4
19 0.6 99.9 86.0 64.4
20 1.0 99.8 78.7 64.5
21 1.6 99.8 79.8 64.6
22 2.8 99.6 79.9 64.9
23 4.8 99.3 78.7 65.3
24 8.4 98.5 75.9 66.0
25 13.5 96.8 69.9 66.8
Cutoff score = 26 21.7 93.4 64.6 68.2
27 33.5 85.9 56.9 69.9
Normal cognition (n = 10,741) versus AD dementia (n = 6814)
18 29.1 100.0 99.8 66.5
19 33.2 99.9 99.8 67.8
20 38.8 99.8 99.4 69.7
21 45.0 99.8 99.3 71.9
22 52.0 99.6 98.9 74.5
23 59.3 99.3 98.3 77.4
Cutoff score = 24 67.0 98.5 97.0 80.8
25 67.0 98.5 97.0 80.8
MCI (n = 5883) versus AD dementia (n = 6814)
18 29.1 99.4 98.4 52.3
19 33.2 99.0 97.6 53.7
20 38.8 98.4 96.8 55.7
21 45.0 97.2 95.3 58.0
22 52.0 95.2 93.3 60.8
23 59.3 91.6 90.1 63.8
Cutoff score = 24 59.3 91.6 90.1 63.8
25 74.7 78.3 81.5 70.7
Abbreviations: NACC National Alzheimer’s Coordinating Center, MMSE Mini
Mental State Examination, MCI mild cognitive impairment, AD Alzheimer’s
disease, PPV positive predictive value, NPV negative predictive value
PPV and NPV are based on the prevalence of MCI and AD dementia in this
sample. We present values beginning at cutoffs commonly used for
determining MCI (≤26) and AD dementia (≤24) in clinical trials and diagnostic
studies. MMSE scores <18 continued to decline in NPV and increase in PPV
and thus are not presented
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NPVs for MMSE and LM-II cutoff scores across all diag-
nostic classifications that were most alarming, however.
The PPV was only 64 % for the MMSE cutoff often used
to define MCI (or early AD dementia) in AD trials and
diagnostic studies. The PPVs and NPVs were remarkably
low for LM-II cutoffs and spanned the entire AD
spectrum, with many PPVs and NPVs below 50 %, and as
low as 33 % and 42 %, respectively. Given NACC’s large
sample and representativeness of the target clinical trial
population (NACC is an important recruitment source for
AD trials), there is a strong possibility that many of the
multicenter studies in which investigators are testing AD
therapeutic and diagnostic methods include subjects from
a nontarget population. Such inappropriate sampling
could potentially lead to biased or inaccurate results.
The psychometric limitations of the MMSE and LM
(e.g., large ceiling and floor effects, learning biases) limit
their diagnostic accuracy. The MMSE and LM are highly
influenced by demographic factors (e.g., age, education)
[11, 31–33]. Many patients with MCI and mild AD de-
mentia can perform within the “normal” range, and cog-
nitively intact individuals can frequently score within the
impaired range (healthy older adults commonly exhibit
impaired retention on the WMS) [16]. Subjects in AD
trials and diagnostic studies are likely to have had re-
peated exposure to the MMSE and LM, given that they
Table 4 PPV and NPV for AD clinical trial and diagnostic study LM-II cutoff scores for normal cognition versus MCI in NACC
Sensitivity Specificity PPV NPV
LM-II score (A4 Trial) (10,741 normal cognition; 5883 MCI)
Cutoff score = 6 40.5 91.1 71.4 73.6
LM-II score (BAN2401 Trial)
50–64 years (2315 normal cognition; 897 MCI)
Cutoff score = 15 92.1 27.8 33.1 90.1
65–69 years (2092 normal cognition; 909 MCI)
Cutoff score = 12 77.7 52.0 41.3 84.3
70–74 years (2083 normal cognition; 1182 MCI)
Cutoff score = 11 78.1 57.3 50.9 82.1
75–79 years (1824 normal cognition; 1270 MCI)
Cutoff score = 9 67.0 70.0 60.9 75.2
80–90 years (2212 normal cognition; 1472 MCI)
Cutoff score = 7 54.8 80.7 65.4 72.8
LM-II score (ADNI 2)
16+ years of education (6583 normal cognition; 3202 MCI)
Cutoff score = 9 66.4 80.2 62.1 83.0
Cutoff score = 10 73.4 73.0 57.0 84.9
Cutoff score = 11 79.8 64.4 52.2 86.7
8–15 years of education (4061 normal cognition; 2576 MCI)
Cutoff score = 5 35.6 91.3 72.2 69.1
Cutoff score = 6 44.0 86.4 67.2 70.9
Cutoff score = 7 52.5 80.4 62.9 72.7
Cutoff score = 8 60.2 73.1 58.7 74.3
Cutoff score = 9 68.4 64.5 55.0 76.3
0–7 years of education (51 normal cognition; 85 MCI)
Cutoff score = 3 33.7 82.4 76.3 42.4
Cutoff score = 4 44.2 76.5 76 44.8
Cutoff score = 5 54.7 74.5 78.3 49.4
Abbreviations: NACC National Alzheimer’s Coordinating Center, MMSE Mini Mental State Examination, LM-II Wechsler Memory Scale Logical Memory-II, MCI mild
cognitive impairment, ADNI 2 Alzheimer’s Disease Neuroimaging Initiative 2, PPV positive predictive value, NPV negative predictive value
PPV and NPV are based on the prevalence of MCI in each of the age or educational categories. Cutoffs were chosen on the basis of those used in AD clinical trials
and diagnostic studies: “Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease” (6–18 = asymptomatic AD); “A Placebo-controlled, Double-blind, Parallel-
group, Bayesian Adaptive Randomization Design and Dose-Regimen-find Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early
Alzheimer’s Disease” (50–64 years: ≤15; 65–69 years: ≤12; 70–74 years: ≤11; 75–79 years: ≤9; 80–90 years ≤7); and ADNI 2 (16 years of education: normal ≥9; early
MCI 9–11; AD ≤8; 8–15 years of education: normal ≥5; early MCI 5–9; AD ≤4; 0–7 years of education: normal ≥3; early MCI 3–6; AD ≤2)
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are among the most widely used measures in the clinical
management of AD and are included in many research
registries (e.g., NACC ADCs). Both instruments are sen-
sitive to practice effects and subsequent inflated scores;
in fact, past work has shown that subjects with MCI
from ADNI demonstrated practice effects only for LM
[34]. It is the psychometric weaknesses of the MMSE
and LM-II that underpin their lack of utility as stand-
alone diagnostic measures, and their isolated use to de-
termine inclusion into AD trials and diagnostic studies
could lead to inappropriate sampling and affect the val-
idity and reliability of study results [18, 19].
There was an overall lack of agreement between MMSE
and CDR scores among NACC subjects. The CDR is con-
sidered the gold standard for staging dementia severity,
and the MMSE appears to lack validity in detecting and
discriminating across the various disease stages, particu-
larly at the mild end of the spectrum [35]. This has signifi-
cant economic, clinical, and research implications, given
that clinical trials rely on the MMSE to distinguish be-
tween subjects with normal cognition, MCI, and AD de-
mentia when determining inclusion. Moreover, national
guidelines in parts of the world use the MMSE to define
dementia severity to guide pharmacological intervention
[36, 37].
There is a need to improve upon current study inclu-
sion methods for AD clinical trials and diagnostic stud-
ies. The continued use of existing brief, inexpensive
methods for determining entry into AD trials may lead
to inaccurate study findings, including failure to meet
endpoints, because of inappropriate inclusion of subjects
into the trials, rather than lack of efficacy of the com-
pounds being studied. With the tremendous amount of
time and financial resources devoted to the development
of new and cutting edge AD therapeutics and diagnostic
methods, it may be time to set aside this “penny-wise and
pound-foolish” approach to the selection of screening
and/or selection instruments and devote adequate time
and resources to the development of rigorous new mea-
sures that may be expensive and time-consuming, but
would increase the accurate detection of the appropriate
population and do justice to the science at hand. This
would require development of specific tests based on the
specific goal of the screening, focusing on cognitive (or
Table 5 PPV and NPV for AD clinical trial and diagnostic study LM-II cutoff scores for normal cognition versus AD dementia in NACC
Sensitivity Specificity PPV NPV
LM-II score (A4 Trial) (10,741 normal cognition; 6814 AD dementia)
Cutoff score = 6 89.0 91.1 86.4 92.9
LM-II score (BAN2401 Trial)
50–64 years (2315 normal cognition; 995 AD dementia)
Cutoff score = 15 99.4 27.8 37.2 99.1
65–69 years (2092 normal cognition; 722 AD dementia)
Cutoff score = 12 98.5 52.0 41.4 99.0
70–74 years (2083 normal cognition; 1082 AD dementia)
Cutoff score = 11 97.3 57.3 54.2 97.6
75–79 years (1824 normal cognition; 1562 AD dementia)
Cutoff score = 9 96.2 70.0 73.3 95.6
80–90 years (2212 normal cognition; 2263 AD dementia)
Cutoff score = 7 93.9 80.7 83.3 92.9
LM-II score (ADNI 2)
16+ years of education (6583 normal cognition; 3118 AD dementia)
Cutoff score = 8 92.4 90.9 82.8 96.2
8–15 years of education (4061 normal cognition; 3518 AD dementia)
Cutoff score = 4 84.4 94.6 93.1 87.5
0–7 years of education (51 normal cognition; 143 AD dementia)
Cutoff score = 2 77.8 88.2 94.9 58.4
Abbreviations: NACC National Alzheimer’s Coordinating Center, MMSE Mini Mental State Examination, MCI mild cognitive impairment, LM-II Wechsler Memory Scale
Logical Memory-II, ADNI 2 Alzheimer’s Disease Neuroimaging Initiative 2, PPV positive predictive value, NPV negative predictive value
PPV and NPV are based on the prevalence of AD dementia in each of the age or educational categories. Cutoffs were chosen on the basis of those used in AD
clinical trials and diagnostic studies: “Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease” (6–18 = asymptomatic AD); “A Placebo-controlled, Double-
blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose-Regimen-find Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects
with Early Alzheimer’s Disease” (50–64 years: ≤15; 65–69 years: ≤12; 70–74 years: ≤11; 75–79 years: ≤9; 80–90 years ≤7); and ADNI 2 (16 years of education:
normal ≥9; early MCI 9–11; AD ≤8; 8–15 years of education: normal ≥5; early MCI 5–9; AD ≤4; 0–7 years of education: normal ≥3; early MCI 3–6; AD ≤2)
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other) domains, with appropriate variability (diminished
floor and ceiling effects), extensive normative and clinical
data, and attention to cultural and language differences.
Alternatively, there are existing instruments and method-
ology that could be implemented that may facilitate ap-
propriate enrollment. For example, a recent study in
ADNI found optimal diagnostic certainty of MCI included
<1 standard deviation below normative reference on two
episodic memory measures (LM-II and Auditory Verbal
Learning Test delay recall) [38]. If AD clinical trials and
diagnostic studies continue to rely on single screening
measures due to their time- and cost-effectiveness, it is
encouraged that more stringent criterion cutoffs be used
[39] and the methodology employed in this paper be used
(i.e., calculation of PPV, NPV) to identify the best cutoffs
for accurate diagnostic classification using existing mea-
sures. However, instead of relying on the MMSE, more
comprehensive screening tools, such as the Montreal Cog-
nitive Assessment (MoCA), may be helpful. The MoCA
has been shown to demonstrate greater predictive ability
of dementia and have lower ceiling effects than the MMSE
[40, 41]. In sum, the specific solution for optimizing
inclusion methods for AD trials is unclear, but alternatives
need to be considered, including the possibility of aban-
doning current practice and developing new methods.
The present study is not without limitations. The
generalizability of the PPVs and NPVs is restricted to the
NACC sample, a convenience research sample. However,
this concern is attenuated, given that many clinical trials
and diagnostic studies recruit from NACC sites. The
cross-sectional data may have precluded robust diagnos-
tic status within the NACC sample. Longitudinal studies
are needed to clarify the limitations of the MMSE and
LM across diagnostic severity groups, including their
sensitivity to change and the role of practice effects, par-
ticularly in the context of recent work from the NACC
dataset that shows most pronounced practice effects
over time (relative to other measures from the UDS) on
tasks of semantic and episodic memory [42].
Conclusions
The use of MMSE and LM-II scores to determine eligi-
bility for AD clinical trials and diagnostic studies may
lead to inappropriate inclusion or exclusion of subjects.
Table 6 PPV and NPV for AD clinical trial and diagnostic study LM-II cutoff scores for MCI versus AD dementia in NACC
Sensitivity Specificity PPV NPV
LM-II score (A4 Trial) (5883 MCI; 6814 AD dementia)
Cutoff score = 6 89.0 51.8 68.1 80.3
LM-II score (BAN2401 Trial)
50–64 years (897 MCI; 995 AD dementia)
Cutoff score = 15 99.4 5.3 53.9 88.9
65–69 years (909 MCI; 722 AD dementia)
Cutoff score = 12 98.5 16.2 48.2 93.1
70–74 years (1182 MCI; 1082 AD dementia)
Cutoff score = 11 97.3 15.9 51.5 86.7
75–79 years (1270 MCI; 1562 AD dementia)
Cutoff score = 9 96.2 26.2 61.5 85.0
80–90 years (1472 MCI; 2263 AD dementia)
Cutoff score = 7 93.9 37.8 69.8 80.2
LM-II score (ADNI 2)
16+ years of education (3202 MCI; 3118 AD dementia)
Cutoff score = 8 92.4 48.3 63.5 86.8
8–15 years of education (2576 MCI; 3518 AD dementia)
Cutoff score = 4 84.4 64.4 76.4 75.1
0–7 years of education (85 MCI; 143 AD dementia)
Cutoff score = 2 77.8 66.3 79.6 64.0
Abbreviations: NACC National Alzheimer’s Coordinating Center, MMSE Mini Mental State Examination, MCI mild cognitive impairment, LM-II Wechsler Memory Scale
Logical Memory-II, ADNI 2 Alzheimer’s Disease Neuroimaging Initiative 2, PPV positive predictive value, NPV negative predictive value
PPV and NPV are based on the prevalence of AD dementia in each of the age or educational categories. Cutoffs were chosen on the basis of those used in AD
clinical trials and diagnostic studies: “Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease” (6–18 = asymptomatic AD); “A Placebo-controlled, Double-
blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose-Regimen-find Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects
with Early Alzheimer’s Disease” (50–64 years: ≤15; 65–69 years: ≤12; 70–74 years: ≤11; 75–79 years: ≤9; 80–90 years ≤7); and ADNI 2 (16 years of education: normal
≥9; early MCI 9–11; AD ≤8; 8–15 years of education: normal ≥5; early MCI 5–9; AD ≤4; 0–7 years of education: normal ≥3; early MCI 3–6; AD ≤2)
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Such biases in sample selection could translate to mis-
leading results from trials testing the efficacy of new AD
treatments, or diagnostic studies examining methods
and biomarkers for the detection of AD.
Abbreviations
AD: Alzheimer’s disease; ADC: Alzheimer’s Disease Center; ADNI: Alzheimer’s
Disease Neuroimaging Initiative; AUC: area under the receiver operating
characteristic curve; CDR: Clinical Dementia Rating; LM: Logical Memory;
MCI: mild cognitive impairment; MMSE: Mini Mental State Examination;
MoCA: Montreal Cognitive Assessment; NACC: National Alzheimer’s
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predictive value; ROC: receiver operating characteristic; SD: standard
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